| Ashishkumar Amritlal Vachhani, MD | |
|
110 Kingsley Ln, Suite 305, Norfolk, VA 23505-4614 | |
| (757) 889-5942 | |
| (804) 266-3530 |
| Full Name | Ashishkumar Amritlal Vachhani |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 26 Years |
| Location | 110 Kingsley Ln, Norfolk, Virginia |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831177450 | NPI | - | NPPES |
| 010109019 | Medicaid | VA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 0101236684 (Virginia) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 0101236684 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Sentara Princess Anne Hospital | Virginia beach, VA | Hospital |
| Sentara Virginia Beach General Hospital | Virginia beach, VA | Hospital |
| Sentara Obici Hospital | Suffolk, VA | Hospital |
| Bon Secours Maryview Medical Center | Portsmouth, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hampton Roads Radiology Associates, Pc | 4880688506 | 39 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
Scientists at Carnegie Mellon University's Molecular Biosensor and Imaging Center have developed new "fluorogen activating proteins" (FAPs) that will become a key component of novel molecular biosensor technology being created at Carnegie Mellon.
Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).
A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.
A United Kingdom study designed to examine the association between primary care practitioner empathy and incidence of cardiovascular disease and all-cause mortality among type 2 diabetes patients found that those patients experiencing greater empathy in the year following their diagnosis saw beneficial long-term clinical outcomes.
› Verified 2 days ago
| Entity Name | Hampton Roads Radiology Associates, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174533624 PECOS PAC ID: 4880688506 Enrollment ID: O20041123000788 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
Scientists at Carnegie Mellon University's Molecular Biosensor and Imaging Center have developed new "fluorogen activating proteins" (FAPs) that will become a key component of novel molecular biosensor technology being created at Carnegie Mellon.
Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).
A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.
A United Kingdom study designed to examine the association between primary care practitioner empathy and incidence of cardiovascular disease and all-cause mortality among type 2 diabetes patients found that those patients experiencing greater empathy in the year following their diagnosis saw beneficial long-term clinical outcomes.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ashishkumar Amritlal Vachhani, MD 110 Kingsley Ln Ste 305, Norfolk, VA 23505-4617 Ph: (757) 889-5422 | Ashishkumar Amritlal Vachhani, MD 110 Kingsley Ln, Suite 305, Norfolk, VA 23505-4614 Ph: (757) 889-5942 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
Scientists at Carnegie Mellon University's Molecular Biosensor and Imaging Center have developed new "fluorogen activating proteins" (FAPs) that will become a key component of novel molecular biosensor technology being created at Carnegie Mellon.
Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).
A study by Yale School of Medicine researchers reveals that the illnesses and injuries that can restrict the activity of older adults or land them in the hospital are linked to worsening functional ability, especially among those who are physically frail. The report appears in JAMA's November 3 theme issue on aging.
A United Kingdom study designed to examine the association between primary care practitioner empathy and incidence of cardiovascular disease and all-cause mortality among type 2 diabetes patients found that those patients experiencing greater empathy in the year following their diagnosis saw beneficial long-term clinical outcomes.
› Verified 2 days ago
Dr. Kevin Halista, M.D. Radiology Medicare: May Accept Medicare Assignments Practice Location: 110 Kingsley Ln, Suite 305, Norfolk, VA 23505 Phone: 804-262-6900 | |
Dr. Julie Anne Krumreich, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 218 E 42nd St, Norfolk, VA 23504 Phone: 757-963-6713 | |
Norbertina L Banson, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 835 Glenrock Rd, Ste 100a, Norfolk, VA 23502 Phone: 757-252-3370 Fax: 757-252-3225 | |
Mark Cockerill, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 150 Kingsley Ln, Norfolk, VA 23505 Phone: 757-889-5422 Fax: 757-889-5450 | |
Dr. Marc L Pessar, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 850 Kempsville Rd, Norfolk, VA 23502 Phone: 757-466-5910 Fax: 757-466-5748 | |
Dr. Suraj Jaisinghani, MD Radiology Medicare: Medicare Enrolled Practice Location: 600 Gresham Dr, Norfolk, VA 23507 Phone: 585-922-2932 | |
Todd Matthew Berry, MD Radiology Medicare: May Accept Medicare Assignments Practice Location: 110 Kingsley Ln Ste 305, Norfolk, VA 23505 Phone: 757-889-5422 Fax: 757-889-5450 |